Seonglae ChoPainkiller Products
PainkillerActive Compound
The first non-opioid painkiller
The non-opioid painkiller 'Journavx' (generic name: suzetrizine) developed by Vertex received FDA approval on January 30, 2025. While traditional opioids block pain sensations by acting on μ-receptors in the central nervous system, Journavx selectively blocks NaV1.8 ion channels found only in peripheral pain receptors, preventing pain signals from being transmitted to the brain.
Since it doesn't affect the brain, there's no risk of euphoria, respiratory depression, or addiction, and side effects are minimized. Currently approved only for acute pain, clinical trials for chronic pain indications (e.g., diabetic neuropathy) are ongoing. Priced at approximately $230 for a one-week supply, it's more expensive than mild opioids, making expanded insurance coverage a challenge.
The first non-opioid painkiller
Journavx was approved this year. Why did it take so long to develop?
https://www.worksinprogress.news/p/the-first-non-opioid-painkiller
A next-gen pain drug shows promise, but chronic sufferers need more options
A new painkiller nearing approval called suzetrigine may prove to be an opioid alternative. But for many with chronic pain, treatment must go beyond pills.
https://www.sciencenews.org/article/next-gen-drug-chronic-pain-alternative
How do painkillers kill pain? It's about meeting the pain where it's at
Without the ability to feel pain, life is more dangerous. To avoid injury, pain tells us to use a hammer more gently, wait for the soup to cool or put on gloves in a snowball fight.
https://arstechnica.com/science/2022/07/how-do-painkillers-kill-pain-its-about-meeting-the-pain-where-its-at/
